For one, a product called dotinurad already approved in Japan ... This is not a new idea: drugs including benzbromarone and lesinurad (Zurampic) also block URAT1, but they both have safety ...

The randomized, placebo-controlled Phase 1 clinical trial evaluated the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of ...

Results from a randomized controlled trial conducted in China found low-dose benzbromarone to be more effective in lowering serum urate levels than low-dose febuxostat (Uloric), with a similar ...

The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom ...

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic ...

Benzbromarone, a urate-lowering drug, appeared effective among patients with high serum uric acid levels who had no evidence of gout flares. Benzbromarone may reduce the risk of developing chronic ...

Benzbromarone demonstrated slightly greater efficacy for the rapid reduction of serum uric acid levels and offered greater anti-inflammatory effects vs febuxostat for the treatment of gout and ...

Dotinurad for the treatment of gout and Triplex for the treatment of cytomegalovirus continue to advance in clinical trials and we anticipate a dotinurad Phase 1 topline data readout in U.S ...

Eisai and Fuji Yakuhin Co., Ltd announced that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by Fuji Yakuhin, for ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n366vw/benzbromarone) has announced the addition of the "Benzbromarone (CAS ...